Related Experiment Video
Updated: Jun 13, 2026
04:41
Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
Amyloid-beta fibrils as active contributors to synaptic dysfunction in Alzheimer's disease
Nunzia Maisto1, Giorgia Ciufolini2, Sepideh Dashtiani1,3
1School of Pharmacy, Department of Biology, University of Rome 'Tor Vergata', 00133, Rome, Italy.
Acta Pharmacologica Sinica
|June 11, 2026
Summary
Alzheimer's disease research shows amyloid-beta (Aβ) fibrils, not just oligomers, significantly impair synaptic plasticity and membrane integrity, contributing to cognitive decline.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Alzheimer's disease (AD) is linked to amyloid-beta (Aβ) aggregates.
- Aβ oligomers are often considered the primary toxic species.
- The specific role of Aβ fibrils in neuronal dysfunction, particularly synaptic plasticity, remains under-investigated.
Purpose of the Study:
- To investigate the impact of Aβ fibrils on neuronal function and membrane integrity.
- To compare the neurotoxicity of Aβ fibrils versus Aβ oligomers.
- To elucidate the contribution of Aβ fibrils to synaptic defects in Alzheimer's disease.
Main Methods:
- Generated Aβ fibrils from Aβ₁-42 oligomers.
- Evaluated effects on synaptic plasticity in ex vivo mouse hippocampal slices.
- Utilized a liposomal model to study fibril-membrane interactions.
Main Results:
- Aβ fibrils caused more severe damage to synaptic plasticity than Aβ oligomers.
- Aβ fibrils altered membrane fluidity, unlike Aβ oligomers.
- Fibril size and aggregation state were identified as critical factors in toxicity.
Conclusions:
- Aβ fibrils play a significant role in Alzheimer's disease pathogenesis.
- Fibrils contribute to synaptic dysfunction and cellular damage, impacting cognitive function.
- Findings challenge the notion that oligomers are the sole primary toxic species in AD.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...